Sedative-Hypnotics | Steve Batki, MD

This lecture covers the pharmacology, epidemiology, diagnosis, detox, and treatment of benzodiazepine substance use disorders.


You must sign in or register register on this site before purchasing using the link on the upper right corner of this page. Only after registering will you see the "Add to Cart" button. To purchase, scroll to the bottom of the page and click "Add to Cart."  


PHYSICIANS: The California Society of Addiction Medicine (CSAM) is accredited by the Institute for Medical Quality/California Medical Association to provide continuing medical education for physicians.  CSAM takes responsibility for the content, quality and scientific integrity of this CME activity.

CSAM designates this live educational activity for a maximum of 1 AMA PRA Category 1 Credit™ Physicians should only claim credit commensurate with the extent of their participation in the activity. This credit may also be applied to the CMA Certification in Continuing Medical Education.

This course has been approved by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 1 AMA/PRA Category 1 Credits™ for completing the Review Course.

Continuing education credit is also available for nurses, psychologists, pharmacists, physician assistants, therapists, and drug abuse counselors. 

Target Audience

  • Addiction medicine specialists who want an overview of the latest developments in the field and their relevance to clinical practice
  • Primary care clinicians who want to get a better understanding of addiction and manage patients with addictions in their practice
  • Public health officials who want an understanding of the current state of addiction treatment
  • Non-physicians who are involved in the treatment of addiction

Learning Objectives

After viewing this lecture participants should be able to

  1. Recognize benzodiazepine withdrawal syndromes
  2. Discuss the pharmacology of bwenzodiazpeines
  3. Use epidemiological data to help assess the risk of benzodiazepine use disorders
  4. Apply an understanding of the risk of mixing benzodiazepines and opioids
  5. Assess methods of tapering from benzodiazepines (BZs) in different patients


Course summary
Available credit: 
  • 1.00 AMA Category 1
  • 1.00 Attendance
Course opens: 
Course expires: 

Steven L. Batki, MD
Steven L. Batki, M.D. is Professor of Psychiatry at the University of California, San Francisco (UCSF) School of Medicine, Director of the Addiction Recovery Treatment Services at the San Francisco VA Medical Center where he also directs the Addiction Research Program and the UCSF/SFVAMC Addiction Psychiatry Fellowship Program. Previously, he served as Director of the Division of Substance Abuse and Addiction Medicine at San Francisco General Hospital. Dr. Batki also serves as the Addiction Psychiatry Consultant for Alta Mira Recovery Programs, a residential rehabilitation program in Sausalito, CA. Dr. Batki is engaged in addiction research, training, and clinical services. His research focuses on the pharmacological treatment of addiction and co-occurring psychiatric and medical disorders.

Dr. Batki has no relevant financial relationships to disclose.

Available Credit

  • 1.00 AMA Category 1
  • 1.00 Attendance


Please login or register to take this course.